Real-World Data on Luspatercept in LR-MDS

Saeed Sadeghi, MD, reviews real-world data on luspatercept, discussing treatment patterns and outcomes, including transfusion burden, hemoglobin increase, and other key baseline data that may differ from registrational studies in the context of managing lower-risk myelodysplastic syndromes (LR-MDS).

EP: 1.Mechanism of Action: Luspatercept vs Epoetin Alfa in LR-MDS

EP: 2.COMMANDS Study Update: Luspatercept vs. Epoetin Alfa in 1L Treatment

Now Viewing

EP: 3.Real-World Data on Luspatercept in LR-MDS

EP: 4.Health Care Resource Utilization: Luspatercept vs ESAs in MDS

EP: 5.Current Approach to Treating Anemia in LR-MDS

EP: 6.Future Perspective on Anemia Treatment in LR-MDS

Video content above is prompted by the following:

Now that luspatercept has been available for a while, we have real-world data reports.

Recent Videos